Table 4 Antioxidant screening results of the synthesized compounds (T1T20)

From: Synthesis and biological evaluation of heterocyclic 1,2,4-triazole scaffolds as promising pharmacological agents

Compounds % inhibition IC50 (µg/ml)
25 (µg/ml) 50 (µg/ml) 75 (µg/ml) 100 (µg/ml)
T1 25.45 49.65 69.67 94.78 46.83
T2 45.67 56.98 70.16 84.21 34.83
T3 43.56 60.12 75.67 88.98 34.38
T4 38.45 58.34 88.61 98.89 37.50
T5 42.34 55.67 68.98 78.12 39.13
T6 31.67 53.67 77.78 92.67 45.66
T7 46.75 52.56 60.56 70.41 38.54
T8 43.91 58.67 67.54 82.57 36.12
T9 40.56 60.67 83.61 92.16 35.42
T10 45.56 51.56 57.57 62.67 43.57
T11 35.78 52.89 70.89 89.9 45.36
T12 44.45 51.45 68.56 70.61 39.56
T13 43.46 57.67 73.76 89.56 36.40
T14 37.56 60.68 85.79 95.61 37.52
T15 38.56 50.64 62.16 80.56 47.99
T16 43.65 51.45 67.26 81.76 41.30
T17 48.75 62.57 78.16 84.61 24.90
T18 39.59 68.57 80.13 95.89 33.34
T19 38.45 58.34 80.61 96.89 38.99
T20 33.45 53.67 70.46 92.67 46.34
Ascorbic acid 38.67 63.68 84.78 94.45 35.44
  1. Italics signifies the most active compound in comparison to the standard compound